Skip to main content


Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice

Fig. 5

Evaluation of potential immunotoxicity in in vitro/in vivo assays and effects of treatment withdrawal. a Numbers of T regulatory (Treg) cells (CD3+CD4+CD25hiFoxp3+), CD8+ T cells (CD3+CD8+CD4) and natural killer (NK) cells (CD3CD49bhi) in DBA/1 mice immunized with glucose-6-phosphate isomerase (G6PI) + complete Freund’s adjuvant and exposed to treatment daily for 31 days. b Cell-mediated cytotoxicity assay with splenocytes either treated in vivo (left) or in vitro (right) and YAC-1 as target cells. c Phagocytic activity of peripheral blood mononuclear cells (PBMC) treated in vitro. d Time course for arthritis scores and numbers of Treg cells and NK cells in the spleen of G6PI-immunized mice treated for 35 days and sacrificed on day 47. Graphs show mean (+ standard error of the mean) for 2–6 mice/group, *p <0.05 versus vehicle or media control, # p <0.05 versus non-immunized and untreated group (naive). N naive, Veh vehicle, Predni prednisolone, TC target cells, Med media, JAKi Janus kinase inhibitor, SYKi spleen tyrosine kinase inhibitor

Back to article page